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Background
An accurate, noninvasive test could improve the effectiveness of colorectal-cancer 
screening.
Methods
We compared a noninvasive, multitarget stool DNA test with a fecal immunochem-
ical test (FIT) in persons at average risk for colorectal cancer. The DNA test includes 
quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3 meth-
ylation, and β-actin, plus a hemoglobin immunoassay. Results were generated with 
the use of a logistic-regression algorithm, with values of 183 or more considered to 
be positive. FIT values of more than 100 ng of hemoglobin per milliliter of buffer 
were considered to be positive. Tests were processed independently of colonoscopic 
findings.
Results
Of the 9989 participants who could be evaluated, 65 (0.7%) had colorectal cancer 
and 757 (7.6%) had advanced precancerous lesions (advanced adenomas or sessile 
serrated polyps measuring ≥1 cm in the greatest dimension) on colonoscopy. The 
sensitivity for detecting colorectal cancer was 92.3% with DNA testing and 73.8% 
with FIT (P = 0.002). The sensitivity for detecting advanced precancerous lesions was 
42.4% with DNA testing and 23.8% with FIT (P<0.001). The rate of detection of 
polyps with high-grade dysplasia was 69.2% with DNA testing and 46.2% with FIT 
(P = 0.004); the rates of detection of serrated sessile polyps measuring 1 cm or more 
were 42.4% and 5.1%, respectively (P<0.001). Specificities with DNA testing and FIT 
were 86.6% and 94.9%, respectively, among participants with nonadvanced or neg-
ative findings (P<0.001) and 89.8% and 96.4%, respectively, among those with 
negative results on colonoscopy (P<0.001). The numbers of persons who would 
need to be screened to detect one cancer were 154 with colonoscopy, 166 with DNA 
testing, and 208 with FIT.
Conclusions
In asymptomatic persons at average risk for colorectal cancer, multitarget stool 
DNA testing detected significantly more cancers than did FIT but had more false 
positive results. (Funded by Exact Sciences; ClinicalTrials.gov number, NCT01397747.)
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Colorectal cancer is a major cause of death and disease among men and women in the United States.1 The underly-
ing neoplastic processes of colorectal carcino-
genesis lend themselves to screening.2 Evidence 
supports and guidelines endorse several tests and 
strategies,3-5 and screening for colorectal cancer 
has been found to be cost-effective.5-7
Despite the supporting evidence, recommenda-
tions, and availability of several screening tests, 
a substantial proportion of the U.S. population is 
not up to date with screening.8 A simple, nonin-
vasive test with high sensitivity for both colorectal 
cancer and advanced precancerous lesions might 
increase uptake and adherence rates, which could 
improve clinical outcomes.
Colorectal cancer arises from accumulated 
genetic and epigenetic alterations, which provide 
a basis for the analysis of stool to identify tumor-
specific changes.9 Large-scale screening studies 
of previously available stool-based DNA tests 
showed only fair sensitivity for the detection of 
colorectal cancer (i.e., the capacity to detect can-
cers, or true positive tests [see Glossary]) and low 
sensitivity for the detection of advanced adeno-
mas.10,11 Important advances have since been in-
corporated, including the use of a stabilizing buf-
fer,12,13 more discriminating markers,14,15 more 
sensitive analytic methods,14,16,17 automation,16 
and an overall determination of results with the 
use of a logistic-regression algorithm, which to-
gether result in higher sensitivity for the detection 
of both cancer and advanced precancerous le-
sions.14,16 However, evaluation of the more recent 
tests was based largely on analyses of archived 
specimens, including those collected from pa-
tients after the diagnosis but before the resec-
tion of colorectal cancer or advanced precancer-
ous polyps.
In this study, we evaluate the multitarget stool 
DNA test as a tool for screening. The primary 
aim was to determine the performance charac-
teristics of the DNA test in the detection of colorec-
tal cancer. The secondary aims were to deter-
mine the performance of the DNA test in the 
detection of advanced precancerous lesions and 
to compare it with a commercially available fecal 
immunochemical test (FIT) for human hemoglo-




From June 2011 through November 2012, we en-
rolled participants in this cross-sectional study at 
90 sites throughout the United States and Canada, 
including private-practice and academic settings. 
The study was approved by the institutional review 
board at each site, and all participants provided 
written informed consent.
The study, which was funded by Exact Sciences, 
was designed by the authors; Health Decisions, 
a contract research organization, gathered and 
monitored the data. The first author wrote the 
first draft of the manuscript, incorporating the 
other authors’ contributions; one of the authors, 
who is a statistician, analyzed the data and, along 
Glossary of Screening Terms
Sensitivity (true positive rate): The proportion of persons with disease who have a positive test (positive test results among persons with 
disease).
Specificity (true negative rate): The proportion of persons without disease who have a negative test (negative test results among persons 
without disease).
False negative rate (1 minus sensitivity): The proportion of persons with disease who have a negative test (negative test results among per-
sons with disease).
False positive rate (1 minus specificity): The proportion of persons without disease who have a positive test (positive test results among 
persons without disease).
Positive predictive value: The proportion of persons with disease among those with a positive test (disease present among those with posi-
tive test results).
Negative predictive value: The proportion of persons without disease among those with a negative test (disease absent among those with 
negative test results).
Number needed to screen: The number of persons who would need to be screened to identify one person with the  disease.
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with the last author, vouches for the data and 
adherence to the study protocol, which is avail-
able with the full text of this article at NEJM.org. 
All the authors signed confidentiality agreements 
with Exact Sciences.
Study Population
The target population was asymptomatic persons 
between the ages of 50 and 84 years who were 
considered to be at average risk for colorectal 
cancer and who were scheduled to undergo screen-
ing colonoscopy. Enrollment was weighted toward 
persons 65 years of age or older in order to in-
crease the prevalence of cancer. We excluded par-
ticipants who had a personal history of colorectal 
neoplasia, digestive cancer, or inflammatory bowel 
disease; had undergone colonoscopy within the 
previous 9 years or a barium enema, computed 
tomographic colonography, or sigmoidoscopy 
within the previous 5 years; had positive results 
on fecal blood testing within the previous 6 months; 
had undergone colorectal resection for any reason 
other than sigmoid diverticula; had overt rectal 
bleeding within the previous 30 days; had a per-
sonal or family history of colorectal cancer; had 
participated in any interventional clinical study 
within the previous 30 days; or were unable or 
unwilling to provide written informed consent.
Clinical Procedures
All participants were required to provide a stool 
specimen and undergo screening colonoscopy 
within 90 days after providing informed consent. 
Stool was collected before routine bowel prepara-
tion. No dietary or medication restrictions were 
required. Colonoscopists were required to describe 
the extent of the examination, document cecal 
visualization, rate the quality of preparation (on a 
modified Aronchick scale),18 and record the size 
and location of lesions.
Although colonoscopists reported the location 
and size of all lesions, only the most advanced 
colorectal epithelial lesion (the index lesion) and 
its location (proximal or distal) were used to cat-
egorize participants for the analysis. If two simi-
larly advanced lesions were present, the larger of 
the two was designated as the index lesion. The 
proximal colon was considered to include the 
splenic flexure and all segments proximal to it, 
an insertion depth of more than 60 cm, or any 
part described by the phrase “right colon”; the 
distal colon was considered to include all other 
segments, an insertion depth of 60 cm or less, 
or any part described by the phrase “left colon.”
The biopsy and surgical specimens underwent 
histopathological analysis at the laboratory typi-
cally used by each study site. Polyps with high-
grade dysplasia or 25% or more villous elements 
in adenomas measuring less than 1 cm, as well 
as sessile serrated or hyperplastic polyps measur-
ing 1 cm or larger, were re-reviewed centrally by 
a gastrointestinal pathologist for confirmation, 
with diagnostic disagreements resolved by con-
sensus of at least two central pathologists.
Primary and Secondary Outcomes
The primary outcome was the ability of the DNA 
test to detect colorectal cancer (i.e., adenocarci-
noma), with disease stage determined with the 
use of the American Joint Committee on Cancer 
(AJCC) staging system.19 The secondary outcome 
was the performance of the DNA test for the detec-
tion of advanced precancerous lesions, including 
advanced adenomas (high-grade dysplasia or with 
≥25% villous histologic features or measuring 
≥1 cm in the greatest dimension) and sessile ser-
rated polyps measuring 1 cm or more in diameter.
Laboratory Procedures
A central biorepository received all stool specimens. 
Laboratory testing was performed without knowl-
edge of the results of either the comparator FIT 
or clinical findings. (Details of stool collection 
and processing for DNA testing are shown in Fig. 
S1 in the Supplementary Appendix, available at 
NEJM.org.) Buffered stool samples were homog-
enized, separated into aliquots, and frozen at −80°C 
on receipt. Stool aliquots were subsequently sent 
in batches to one of three laboratories: Exact Sci-
ences (Madison, WI), Mayo Medical Laboratory 
(Rochester, MN), and Molecular Pathology Labo-
ratory Network (Knoxville, TN). Each laboratory 
received, in a blinded fashion, a similar distribu-
tion of specimens on the basis of colonoscopic 
findings.
The multitarget stool DNA test consists of 
molecular assays for aberrantly methylated BMP3 
and NDRG4 promoter regions, mutant KRAS, and 
β-actin (a reference gene for human DNA quan-
tity), as well as an immunochemical assay for 
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human hemoglobin. Quantitative measurements 
of each marker were incorporated into a validat-
ed, prespecified logistic-regression algorithm, 
with a value of 183 or more indicating that the 
test result was positive (for details, see the Sup-
plementary Appendix). Analytic results were 
transferred to the study’s biostatistician.
FIT (OC FIT-CHEK, Polymedco) was performed 
according to the manufacturer’s instructions with 
the use of the same stool sample used for the 
DNA test.20 Samples were refrigerated on receipt 
and sent in batches to a separate single labora-
tory for blinded analysis. Stool samples with 
more than 100 ng of hemoglobin per milliliter 
of buffer were considered to be positive.20
Statistical Analysis
The study was designed to have a power of 90% 
to test the prespecified hypothesis that the DNA 
test would have a sensitivity of 65% or more for 
the detection of colorectal cancer (AJCC stages I 
through IV) under the null hypothesis, at a one-
sided type I error rate of 0.05. A secondary hypoth-
esis was to rule out a 5% noninferiority margin 
for sensitivity for the detection of colorectal can-
cer with the DNA test as compared with FIT, at a 
one-sided type I error rate of 0.05. Testing of the 
two hypotheses with a power of at least 80% re-
quired the diagnosis of 49 and 56 adjudicated 
colorectal cancers, respectively, which required 
the enrollment of 10,500 to 12,000 participants, 
under the assumption of a colorectal-cancer preva-
lence of 4.5 cases per 1000 population.
We conducted prespecified analyses to deter-
mine the sensitivity of the multitarget DNA test, 
as compared with FIT, for the detection of screen-
ing-relevant colorectal cancer (AJCC stages I 
through III); the specificity of the multitarget 
11,016 Could be evaluated
12,776 Participants provided written
informed consent
1760 Could not be evaluated
464 Withdrew consent
1168 Did not undergo colonoscopy
128 Did not submit stool sample
689 Had multitarget DNA test 
       excluded
474 Had stool samples that could  
not be evaluated owing to
leakage in shipping or repeat
specimen not received before
colonoscopy
213 Had technical failure owing
to insufficient DNA (low
β-actin), hemoglobin sample
volume, stool supernatant for
target capture, or material for
repeat assay
2 Had missing samples
34 Had FIT excluded because of
insufficient hemoglobin sample
304 Had colonoscopy excluded
194 Had negative but incomplete
examinations
94 Did not have insertion to
cecum documented
79 Had poor bowel preparation
21 Had incomplete examination
71 Underwent biopsy, but did not
have pathology result owing to
no tissue or loss of specimen
20 Underwent colonoscopy before
stool collection
19 Underwent colonoscopy >90 days
after enrollment
9989 Were included in the primary
analysis
65 Had colorectal cancer
757 Had advanced precancerous
lesions
2893 Had nonadvanced adenoma
6274 Had negative results
Figure 1. Enrollment and Outcomes.
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DNA stool test (i.e., true negative rate), with ad-
vanced precancerous lesions on colonoscopy ex-
cluded and only nonadvanced adenomas and 
negative results included (the primary measure 
of specificity) and with only negative results in-
cluded (the secondary measure of specificity); 
and the sensitivity of the multitarget stool DNA 
test, as compared with FIT, for the detection of 
advanced precancerous lesions. The analyses 
were based on data from all participants who had 
valid results on multitarget stool DNA testing, 
FIT, and colonoscopy; all reported subgroup 
analyses were prespecified.
For test characteristics, 95% lower boundar-
ies were computed with the use of an exact bi-
nomial test. Lower 95% confidence limits for 
comparative analyses were computed with the 
use of a one-sided McNemar paired-comparisons 
test for the observed difference in sensitivity be-
tween the DNA test and FIT. The Hanley–McNeil 
method was used to calculate P values for the 
analysis of the receiver operating characteristic 
(ROC) curve.21 There were no interim analyses 
of the data. All analyses were conducted with the 




A total of 12,776 participants were enrolled at 90 
sites; 9989 of these participants (78.2%) had re-
sults that could be fully evaluated (Fig. 1). The par-
ticipants whose results could be fully evaluated 
and those whose results could not be fully evalu-
ated differed significantly with respect to mean 
age and race, although the magnitudes of the dif-
ferences were small (Table S1 in the Supplemen-
tary Appendix).
A total of 65 participants who could be 
evaluated were found to have colorectal cancer 
on colonoscopy (prevalence, 0.7%). Of these par-
ticipants, 60 had screening-relevant (stage I to 
III) cancers. A total of 757 participants who 
could be evaluated had advanced precancerous 
lesions (prevalence, 7.6%).
DNA Test Characteristics
Multitarget stool DNA testing identified 60 of 65 
participants with cancer, including 56 of the 60 
participants with screening-relevant cancers, for 
respective sensitivities of 92.3% (95% confidence 
interval [CI], 83.0 to 97.5) and 93.3% (95% CI, 
Table 1. Sensitivity and Specificity of the Multitarget Stool DNA Test and the Fecal Immunochemical Test (FIT) 
















no. no. % no. %
Colorectal cancer
Any 65 60 92.3 (83.0–97.5) 48 73.8 (61.5–84.0)
Stage I to III* 60 56 93.3 (83.8–98.2) 44 73.3 (60.3–83.9)
Colorectal cancer and  
high-grade dysplasia
104 87 83.7 (75.1–90.2) 66 63.5 (53.5–72.7)
Advanced precancerous lesions† 757 321 42.4 (38.9–46.0) 180 23.8 (20.8–27.0)





All nonadvanced adenomas,  
non-neoplastic findings, 
and negative results on 
colonoscopy
9167 1231 86.6 (85.9–87.2) 472 94.9 (94.4–95.3)
Negative results on colonoscopy 4457 455 89.8 (88.9–90.7) 162 96.4 (95.8–96.9)
* These stages of colorectal cancer, as defined by the system recommended by the American Joint Committee on Cancer, 
are associated with an increased rate of cure.
† Advanced precancerous lesions include advanced adenomas and sessile serrated polyps measuring 1 cm or more.
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83.8 to 98.2) (Table 1). Sensitivity did not vary 
significantly according to cancer stage (Fig. 2A) 
or location within the colon (Fig. 2B). Among 
757 participants with advanced precancerous le-
sions, DNA testing detected 321 (42.4%; 95% CI, 
38.9 to 46.0). A total of 69.2% (95% CI, 52.4 to 
83.0) of 39 participants with high-grade dyspla-
sia and 42.4% (95% CI, 32.6 to 52.8) of 99 par-
ticipants with sessile serrated polyps measuring 
1 cm or larger were identified on DNA testing 
(Fig. 2C). The sensitivity of the DNA test was 
higher for distal advanced precancerous lesions 
(177 of 325 [54.5%; 95% CI, 48.9 to 60.0]) than 
for proximal lesions (143 of 431 [33.2%; 95% CI, 
28.8 to 37.8]) (Fig. 2B); test sensitivity increased 
as the lesion size increased (Fig. 2D). The sensi-
tivity for the detection of cancer or advanced pre-
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Figure 2. Sensitivity of the Multitarget Stool DNA Test and the Commercial Fecal Immunochemical Test (FIT),  
According to Subgroup.
Shown are the sensitivities of the DNA test and FIT for the detection of colorectal cancer according to tumor stage 
(Panel A), for the detection of colorectal cancer and advanced precancerous lesions according to the location in the 
colon (Panel B), and for the detection of higher-risk subtypes among participants with advanced precancerous le-
sions (Panel C) and according to lesion size (Panel D). The numbers in parentheses are the number of participants 
in each category. In Panel A, the stage of 1 of 65 colorectal cancers was not available. In Panel B, the location of  
1 of 757 advanced precancerous lesions was not available.
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cording to age or laboratory-testing site (data not 
shown).
Among 9167 participants who had findings 
other than colorectal cancer or advanced precan-
cerous lesions (e.g., nonadvanced adenomas or 
negative results), the specificity of the DNA test 
(true negative rate) was 86.6% (95% CI, 85.9 to 
87.2). Among the 4457 participants with totally 
negative results on colonoscopy, the specificity 
was 89.8% (95% CI, 88.9 to 90.7); within this 
subgroup, the specificity was 94.0% among par-
ticipants younger than 65 years of age and 87.1% 
among those 65 years of age or older (P<0.001).
Comparison with FIT
FIT detected 48 of 65 cancers (73.8%; 95% CI, 
61.5 to 84.0), 44 of 60 AJCC stage I to III cancers 
(73.3%; 95% CI, 60.3 to 83.9), and 180 of 757 
advanced precancerous lesions (23.8%; 95% CI, 
20.8 to 27.0), findings that were all significantly 
inferior to those with DNA testing (Table 1). FIT 
detected 20 of 30 proximal cancers (66.7%) and 
28 of 35 distal cancers (80.0%) (P = 0.35 for the 
comparison between proximal and distal location). 
Comparative results for the detection of cancer 
according to stage and for higher-risk subsets of 
advanced precancerous lesions are shown in Fig-
ure 2. The DNA test was more sensitive than FIT 
for the detection of lesions with high-grade dys-
plasia (69.2% vs. 46.2%, P = 0.004) or sessile ser-
rated polyps measuring 1 cm or more (42.4% vs. 
5.1%, P<0.001) (Fig. 2C) and for the detection of 
advanced precancerous lesions within the size 
ranges observed (Fig. 2D).
DNA testing detected 13 of 60 screening-rel-
evant cancers that were undetected by FIT, where-
as FIT detected 1 cancer that was undetected by 
DNA testing (P<0.001). DNA testing detected 170 
of 757 advanced precancerous lesions (22.5%) that 
were undetected by FIT, whereas FIT detected 29 
such lesions (3.8%) undetected by DNA testing 
(P<0.001).
Among 9167 participants with findings 
 other than colorectal cancer or advanced pre-
cancerous lesions, the specificity of FIT was 
94.9% (95% CI, 94.4 to 95.3). Among 4457 par-
ticipants with negative results on colonoscopy, 
the specificity was 96.4% (95% CI, 95.8 to 96.9). 
In these two subgroups, the specificity values 
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Figure 3. Receiver Operating Characteristic (ROC) 
Curves Comparing DNA Testing and FIT for the  
Detection of Colorectal Cancer and Advanced  
Colorectal Neoplasia.
Shown are ROC curves for the multitarget stool DNA 
test and FIT for the detection of colorectal cancer 
(Panel A) and advanced colorectal neoplasia (colo-
rectal cancer plus advanced precancerous lesions) 
(Panel B). For colorectal cancer, the area under the 
ROC curve was 0.94 for the DNA test and 0.89 for 
FIT (95% confidence interval [CI] for the difference in 
area, 0.003 to 0.10; P = 0.04). For advanced colorectal 
neoplasia, the area under the ROC curve was 0.73 for 
the DNA test and 0.67 for FIT (95% CI for the differ-
ence in area, 0.04 to 0.09; P<0.001). The respective 
performance thresholds were a value of 183 or more 
for the DNA test and more than 100 ng of hemoglobin 
per milliliter of buffer for FIT.
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The specificity of FIT varied minimally accord-
ing to age.
As measured by the area under the ROC curve 
(AUC), the discrimination between colorectal can-
cer and the combination of nonadvanced neopla-
sia and lesser findings was significantly higher 
with DNA testing than with FIT (0.94 vs. 0.89, 
P = 0.04) (Fig. 3A); the AUC values for discrimi-
nation between advanced colorectal neoplasia 
(colorectal cancer plus advanced precancerous le-
sions) and all other findings were 0.73 and 0.67, 
respectively (P<0.001) (Fig. 3B). Positive and nega-
tive predictive values are shown in Table S2 in the 
Supplementary Appendix.
The isolated performance of the hemoglobin 
immunoassay component of the multitarget DNA 
test was similar to that of FIT, with specificities 
of 94.8% and 94.9%, respectively; sensitivities 
were 72.3% and 73.8%, respectively, for the detec-
tion of colorectal cancer and 22.7% and 23.8%, 
respectively, for the detection of advanced pre-
cancerous lesions.
Table 2 shows the number of persons who 
would need to be screened with colonoscopy, 
multitarget DNA testing, and FIT in order to 
detect one colorectal cancer (154 with colonos-
copy, 166 with multitarget DNA testing, and 208 
with FIT) and to detect one advanced precancer-
ous polyp (13, 31, and 55 persons, respectively). 
These calculations show that multitarget DNA 
testing detected clinically significant lesions 
more efficiently than FIT.
Extrapolation to an Expanded Screening 
Population
In an extrapolation of our results to a hypotheti-
cal reference population of 10,000 participants at 
average risk for colorectal cancer, the various 
screening techniques of colonoscopy, DNA testing, 
and FIT would identify, respectively, 65, 60, and 
48 persons with colorectal cancer; 758, 321, and 
180 persons with advanced precancerous lesions; 
2896, 498, and 220 persons with nonadvanced 
adenomas; and 6281, 732, and 248 persons with 
non-neoplastic findings or negative results on colo-
noscopy (Table 3).
The protocol specified the detection of colorec-
tal cancer and advanced precancerous polyps as 
positive findings and the detection of nonadvanced 
adenomas as negative findings. In the hypo-
thetical reference population of 10,000 persons, 
the numbers of persons who would be referred 
for colonoscopy on the basis of positive test re-
sults would be 1611 (16.1%) with DNA testing 
and 696 (7.0%) with FIT. Of the positive test re-
sults, the numbers that would be viewed as false 
positives would be 1230 of 1611 (76.4%) with 
DNA testing and 468 of 696 (67.2%) with FIT. Of 
8389 negative results for DNA testing, 442 (5.3%) 
would be viewed as false negatives, consisting of 
5 cancers and 437 advanced precancerous pol-
yps. Of 9304 negative results for FIT, 595 (6.4%) 
would be viewed as false negatives, consisting of 
17 cancers and 578 precancerous polyps. If non-
advanced adenomas were considered to be posi-
tive findings, then the proportions of positive 
tests viewed as false positives would be 732 of 
1611 (45.4%) with DNA testing and 248 of 696 
(35.6%) with FIT. The numbers of negative tests 
viewed as false negatives would be 2840 of 8389 
(33.9%) with DNA testing and 3271 of 9304 
(35.2%) with FIT. Most of these false negative 
results would be small, nonadvanced adenomas 
(in 2398 of 2840 participants [84.4%] with DNA 
testing and 2676 of 3271 participants [81.8%] 
with FIT), with only rare instances of colorectal 
cancers (5 of 2840 [0.2%] and 17 of 3271 [0.5%], 
respectively).
Discussion
We compared a multitarget stool DNA test with a 
commercial FIT among patients at average risk 
for colorectal cancer. The sensitivity of the DNA 
Table 2. Numbers of Persons Who Would Need to Be Screened with Colonoscopy, Multitarget DNA Test, and FIT  
to Detect One Colorectal Cancer and One Advanced Precancerous Lesion.
Finding Number Needed to Screen (95% CI)
Colonoscopy Multitarget DNA Test FIT
Any colorectal cancer 154 (120–200) 166 (130–217) 208 (156–286)
Stage I to III colorectal cancer 166 (130–217) 178 (140–238) 227 (169–313)
Advanced precancerous lesion 13 (12–14) 31 (28–35) 55 (48–65)
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test for the detection of both colorectal cancer 
(92.3%) and advanced precancerous lesions (42.4%) 
exceeded that of FIT by an absolute difference of 
nearly 20 percentage points. This difference may 
be attributed to the DNA marker and algorithm 
components of the test, since the test performance 
of the hemoglobin immunoassay component of 
the DNA test was nearly identical to that of FIT. 
However, FIT was more specific for the detection 
of both colorectal cancer and advanced precan-
cerous lesions, by absolute differences of 6.6 to 
8.3 percentage points.
Sensitivity is the most important characteris-
tic for screening tests because the primary role of 
such testing is to rule out diseases such as can-
cer. The sensitivity of the DNA test for the detec-
tion of advanced precancerous lesions was ap-
proximately half that for the detection of 
colorectal cancer; it exceeded the performance 
of the FIT overall and in important subsets of le-
sions, including adenomas measuring 2 cm or 
more (in which the prevalence of high-grade 
dysplasia is 5 to 44%22-25) and large, sessile ser-
rated polyps (which may account for up to one 
third of colorectal cancers26,27). In our study, 
DNA testing was associated with a relative in-
crease of 27% in the rate of detection of stage I to 
III colorectal cancers and a relative increase of 
78% in the rate of detection of advanced precan-
cerous lesions, as compared with FIT. A negative 
result on DNA testing reduced the chance of 
having colorectal cancer to a greater extent than 
did a negative result on FIT, from a baseline risk 
of approximately 1 in 154 (0.7%) to 1 in 1675 
(0.06%) after DNA testing and 1 in 556 (0.18%) 
after FIT.
Although high sensitivity is the most impor-
tant attribute of cancer-screening tests, specific-
ity is also important, since it affects the number 
of persons who have positive test results, a major-
ity of whom will have false positive results be-
cause of the low prevalence of cancer. The speci-
ficity of FIT (94.9 to 96.4%) was superior to that 
of the DNA test (86.6 to 89.8%), with false posi-
tive rates of 3.6 to 5.1% and 10.2 to 13.4%, re-
spectively. Positive results on the DNA test in-
creased the probability of having colorectal can-
cer from 0.7% to 3.7%, as compared with 6.9% 
for FIT, and increased the probability of having 
an advanced precancerous lesion from 7.3% to 
19.9%, as compared with 25.9% for FIT.
Two points regarding the specificity of DNA 
testing deserve comment. First, analysis of the 
primary measure of specificity (86.6%) included 
participants with nonadvanced adenomas, which 
can cause the test to be positive, and those with 
a negative result on colonoscopy. Among persons 
with only a negative result on colonoscopy, the 
specificity of the DNA test was nearly 90%, al-
though that was still inferior to the specificity of 
FIT, which exceeded 96%. Second, specificity cor-
related inversely with age. Among participants 
with any findings other than advanced neopla-
sia, specificity varied from 91.5% among par-
ticipants between the ages of 50 and 64 years to 
83.7% among those 65 years of age or older. 
Among persons 50 to 64 years of age with a 
negative result on colonoscopy, the specificity of 
Table 3. Extrapolation of Findings to an Expanded Population of 10,000 Persons at Average Risk for Colorectal Cancer 
Undergoing Screening with Colonoscopy, Multitarget Stool DNA Test, and FIT.*
Colonoscopy Finding
Persons 













 no. no. (%)
Colorectal cancer   65 60 (3.7) 5 (0.06) 48 (6.9) 17 (0.18)
Advanced precancerous lesions  758 321 (19.9) 437 (5.2) 180 (25.9) 578 (6.2)
Nonadvanced adenomas 2896 498 (30.9) 2398 (28.6) 220 (31.6) 2676 (28.8)
Negative results: no colorectal cancer, 
advanced precancerous lesions, 
or nonadvanced adenomas 6281 732 (45.4) 5549 (66.1) 248 (35.6) 6033 (64.8)
* Listed are data from the study that have been extrapolated to a theoretical population of 10,000 persons. 
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the DNA test was 94%, which was similar to that 
of FIT. Age-related variation in specificity could 
be due to the presence of lesions that were missed 
on colonoscopy (which are more prevalent among 
persons older than 70 years28) or to age-related 
DNA methylation.29,30
The performance of FIT in our study was 
similar to that in previous studies in which colo-
noscopy was the reference standard.31,32 For FIT 
in our study, we used the manufacturer’s thresh-
old of 100 ng of hemoglobin per milliliter of 
buffer.20 Whether results would differ with the 
use of another type of FIT is not known; how-
ever, the detection rate with the FIT we used was 
higher than the rate with at least one other FIT.33
A discussion of the role of multitarget stool 
DNA testing in colorectal-cancer screening is be-
yond the scope of this report because it requires 
the assessment of several factors aside from sen-
sitivity and specificity, which are the focus of this 
report. Other factors include performance char-
acteristics of alternative tests, testing intervals, 
complications, costs, patient acceptance, and ad-
herence.34,35 Downstream effects of these factors 
on outcomes, including both cause-specific and 
overall morbidity and mortality, require modeling 
studies to compare various screening tests and 
strategies. Although our study provides some of 
the important values for modeling, it cannot deter-
mine which test or strategy is better or preferred.
Screening rates for colorectal cancer remain 
low despite strong evidence of the effectiveness 
of several tests and strategies. The U.S. Preven-
tive Services Task Force states that there is no 
preferable screening test, as supported by several 
cost-effectiveness analyses.5-7 Offering a choice 
among tests may improve uptake of screening.32,36 
A noninvasive test with a high single-application 
sensitivity for curable-stage cancer may provide 
an option for persons who prefer noninvasive test-
ing. Questions about testing intervals and tailor-
ing require further consideration.
In conclusion, a stool test combining altered 
human DNA and fecal hemoglobin showed high-
er single-application sensitivity than a commercial 
FIT for both colorectal cancer and advanced pre-
cancerous lesions, although with lower specificity.
Supported by Exact Sciences.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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